Table 2.

Treatment-emergent adverse events

	15 μg PD03A (N = 12)	75 μg PD03A (N = 12)	Placebo (N = 12)
Patients with≥1 TEAE; n (%)	12 (100)	12 (100)	12 (100)
Patients with≥1 serious TEAE; n (%)	2 (16.7)	0	3 (25.0)
Patients with any TEAE leading to treatment discontinuation; n	0	0	0
Patients with≥1 local site reaction; n (%)	12 (100)	10 (83.3)	12 (100)
Treatment emergent, treatment-related* systemic AEs occurring in ≥1 patient in any group*
Headache; n (%)	0	1 (8.3)	0
Fatigue; n (%)	0	0	1 (8.3)
Myalgia; n (%)	1 (8.3)	1 (8.3)	0

^*considered probably or certainly related to study treatment.